Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 281-284

  Bosso, John A ^a   Flume, Patrick A ^b   Gray, Susan L ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; FLUTICASONE; IPRATROPIUM BROMIDE; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; SALBUTAMOL; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GRAM POSITIVE BACTERIUM; HEMATOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; OXAZOLIDINONES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0347992027     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.281-284.2004     Document Type: Article

References (20)

1. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
2. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
3. Conte, J. E., Jr., J. A. Golden, J. Kipps, and E. Zurlinden. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480.
4. Ferrin, M., J. B. Zuckerman, A. Meagher, and E. A. Blumberg. 2002. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr. Pulmonol. 33:221-223.
5. FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9.
6. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker, Inc., New York, N.Y.
7. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
8. Hutabarat, R. M., J. D. Unadkat, C. Sahajawalla, S. McNamara, B. Ramsey, and A. L. Smith. 1991. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clin. Pharmacol. Ther. 49:402-409.
9. Jones, R. N., D. M. Johnson, and M. E. Erwin. 1996. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. 40:720-726.
10. Kearns, G. L., S. M. Abdel-Rahman, J. L. Blumer, M. D. Reed, L. P. James, R. F. Jacobs, I. R. Welshman, G. L. Jungbluth, and D. J. Stalker. 2000. Single dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J. 19:1178-1184.
11. Knoppert, D. C., M. Spino, R. Beck, J. J. Thiessen, and S. M. MacLeod. 1988. Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. Clin. Pharmacol. Ther. 44:254-264.
12. Lindsay, C. A., and J. A. Bosso. 1993. Optimization of antibiotic therapy in cystic fibrosis patients. Clin. Pharmacokinet. 24:496-506.
13. Meagher, A. K., A. Forrest, C. R. Rayner, M. C. Birmingham, and J. R. Schentag. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate use program. Antimicrob. Agents Chemother. 47:548-553.
14. Sisson, T. L., G. L. Jungbluth, and N. K. Hopkins. 1999. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J. Clin. Pharmacol. 39:1277-1282.
15. Sisson, T. L., G. L. Jungbluth, and N. K. Hopkins. 2002. Age and sex effects on the pharmacokinetics of linezolid. Eur. J. Clin. Pharmacol. 57:793-797.
16. 14C]linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145.
17. Susanto, M., and L. Z. Benet. 2002. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharmacol. Res. 19:457-462.
18. Thomas, S. R., K. M. Gyi, H. Gaya, and M. E. Hodson. 1998. Methicillin resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J. Hosp. Infect. 40:203-209.
19. Wootton, M., R. A. Howe, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2002. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J. Antimicrob. Chemother. 50:755-766.
20. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, et al. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.